Researchers evaluated 12 randomized controlled trials examining solitary magnesium administration and determined that the overall quality of evidence supporting sleep improvement ranges from low to very low.
Clinical Trials Reveal Inconsistent Sleep Improvements
The Australian research team screened literature and trial registries through June 1, 2026, identifying 12 randomized controlled trials that isolated magnesium as a single intervention for sleep outcomes. Because the trials varied significantly in participant demographics, chemical formulations, dosages, intervention durations, and measurement tools, investigators avoided combining the data into a single numerical average and instead evaluated the studies individually, according to findings reported by the Herald Economy.
Among five trials that scored insomnia severity using standardized point scales, three reported measurable improvements in participants taking magnesium, while two showed no statistically significant difference compared to a placebo. In a 2025 clinical trial where participants ingested magnesium for four weeks, scores on a 28-point insomnia scale dropped by 3.9 points, but individuals receiving a placebo also experienced a 2.3-point reduction. This left a net difference attributable to magnesium of 1.6 points.
Efficacy in Specific Patient Cohorts and Dosing Realities
Trials involving patients with concurrent medical diagnoses demonstrated even less distinct therapeutic benefit. Individuals managing polycystic ovary syndrome, fibromyalgia, and cognitive impairment experienced overall sleep quality outcomes that did not differ meaningfully from control groups taking placebos.
Objective sleep measurements across the literature showed similar limitations. Only one trial conducted in 2002 utilized electroencephalography to track brain waves and confirmed an increase in deep sleep among 12 participants. Wrist-worn research accelerometers failed to reveal clear differences between magnesium and placebo groups, while consumer-grade smart rings produced mixed results, with some trials indicating positive changes and others showing none.
Dosing regimens across the 12 evaluated studies spanned widely from 75 milligrams to 729 milligrams daily. Investigators observed that neither higher doses nor extended durations of intake correlated with increased therapeutic efficacy.
The research team noted a primary methodological limitation across the evaluated literature: the vast majority of trials failed to assess participants’ baseline dietary magnesium intake or pre-existing serum blood concentrations. Consequently, studies that registered no therapeutic effect may have enrolled individuals who already maintained adequate nutritional levels of the mineral.
Worth a look